JP2016538545A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538545A5 JP2016538545A5 JP2016530873A JP2016530873A JP2016538545A5 JP 2016538545 A5 JP2016538545 A5 JP 2016538545A5 JP 2016530873 A JP2016530873 A JP 2016530873A JP 2016530873 A JP2016530873 A JP 2016530873A JP 2016538545 A5 JP2016538545 A5 JP 2016538545A5
- Authority
- JP
- Japan
- Prior art keywords
- liver
- protein
- marker protein
- cell
- marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 claims 37
- 108090000623 proteins and genes Proteins 0.000 claims 37
- 239000003550 marker Substances 0.000 claims 31
- 238000000034 method Methods 0.000 claims 22
- 210000004027 cell Anatomy 0.000 claims 17
- 102000004243 Tubulin Human genes 0.000 claims 16
- 108090000704 Tubulin Proteins 0.000 claims 16
- 208000014018 liver neoplasm Diseases 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 14
- 210000005229 liver cell Anatomy 0.000 claims 11
- 239000000090 biomarker Substances 0.000 claims 10
- 210000005228 liver tissue Anatomy 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 210000004881 tumor cell Anatomy 0.000 claims 8
- 108010019099 Aldo-Keto Reductase Family 1 member B10 Proteins 0.000 claims 6
- 102100026451 Aldo-keto reductase family 1 member B10 Human genes 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 230000027455 binding Effects 0.000 claims 4
- 238000012544 monitoring process Methods 0.000 claims 4
- 102100024682 14-3-3 protein eta Human genes 0.000 claims 3
- 101710188276 14-3-3 protein eta Proteins 0.000 claims 3
- 102000015827 Asporin Human genes 0.000 claims 3
- 108050004044 Asporin Proteins 0.000 claims 3
- 102000047200 Collagen Type XVIII Human genes 0.000 claims 3
- 108010001463 Collagen Type XVIII Proteins 0.000 claims 3
- 102000016359 Fibronectins Human genes 0.000 claims 3
- 108010067306 Fibronectins Proteins 0.000 claims 3
- 102100035220 Plastin-3 Human genes 0.000 claims 3
- 101710081133 Plastin-3 Proteins 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 238000011269 treatment regimen Methods 0.000 claims 3
- 102000012123 Dihydropyrimidinase-related protein 3 Human genes 0.000 claims 2
- 108050002650 Dihydropyrimidinase-related protein 3 Proteins 0.000 claims 2
- 210000000013 bile duct Anatomy 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 230000029087 digestion Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 210000002919 epithelial cell Anatomy 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- 102100036238 Dihydropyrimidinase Human genes 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000007666 Klatskin Tumor Diseases 0.000 claims 1
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 230000010109 chemoembolization Effects 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 108091022884 dihydropyrimidinase Proteins 0.000 claims 1
- 210000002767 hepatic artery Anatomy 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1320061.3 | 2013-11-13 | ||
| GBGB1320061.3A GB201320061D0 (en) | 2013-11-13 | 2013-11-13 | Materials nad methods for diagnosis and prognosis of liver cancer |
| PCT/GB2014/053368 WO2015071669A2 (en) | 2013-11-13 | 2014-11-13 | Materials and methods for diagnosis and prognosis of liver cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016538545A JP2016538545A (ja) | 2016-12-08 |
| JP2016538545A5 true JP2016538545A5 (enExample) | 2018-04-12 |
Family
ID=49818578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016530873A Pending JP2016538545A (ja) | 2013-11-13 | 2014-11-13 | 肝臓癌の診断及び予後判定のための材料及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160320395A1 (enExample) |
| EP (1) | EP3069142A2 (enExample) |
| JP (1) | JP2016538545A (enExample) |
| CA (1) | CA2928510A1 (enExample) |
| GB (1) | GB201320061D0 (enExample) |
| WO (1) | WO2015071669A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105288659B (zh) * | 2015-06-01 | 2019-07-26 | 北京泱深生物信息技术有限公司 | Tenm1基因及其表达产物在诊治乳头状腺癌的应用 |
| KR101750411B1 (ko) | 2015-07-10 | 2017-06-27 | 한국생명공학연구원 | 엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법 |
| WO2017121974A1 (fr) * | 2016-01-15 | 2017-07-20 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Procédé de diagnostic in vitro d'atteintes hépatiques |
| FR3048780B1 (fr) | 2016-03-11 | 2020-11-06 | Commissariat Energie Atomique | Procede de diagnostic in vitro d'atteintes hepatiques |
| GB201616912D0 (en) * | 2016-10-05 | 2016-11-16 | University Of East Anglia | Classification of cancer |
| GB201619954D0 (en) * | 2016-11-25 | 2017-01-11 | Oncimmune Ltd | Antibody assay |
| SG11201906735RA (en) | 2017-01-23 | 2019-08-27 | Regeneron Pharma | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof |
| CN115266962B (zh) * | 2017-03-31 | 2024-05-31 | 北京谷海天目生物医学科技有限公司 | 蛋白标志物在制备弥漫型胃癌分子分型的产品中的应用及弥漫型胃癌分子分型的分类器 |
| JP2020516283A (ja) | 2017-04-11 | 2020-06-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヒドロキシステロイド（１７−ベータ）デヒドロゲナーゼ（ｈｓｄ１７ｂ）ファミリーのメンバーのモジュレーターの活性をスクリーニングするためのアッセイ |
| WO2018189215A1 (en) * | 2017-04-12 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the survival time of a patient suffering from hepatocellular carcinoma |
| KR20240125690A (ko) | 2017-10-11 | 2024-08-19 | 리제너론 파마슈티칼스 인코포레이티드 | Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해 |
| CN109596829A (zh) * | 2017-12-07 | 2019-04-09 | 南京医科大学 | 一种肝癌标志蛋白及其检测方法 |
| WO2019115679A1 (en) * | 2017-12-13 | 2019-06-20 | Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol | A signature to assess prognosis and therapeutic regimen in liver cancer |
| CN112020556A (zh) | 2018-03-21 | 2020-12-01 | 瑞泽恩制药公司 | 第13型17β羟基类固醇脱氢酶(HSD17B13)iRNA组成物及其使用方法 |
| EP3976195A4 (en) * | 2019-05-28 | 2023-10-18 | The Regents Of The University Of California | METHODS OF TREATMENT OF SMALL CELL NEUROENDOCRINAL CANCERS AND ASSOCIATED CANCERS |
| EP4103948A1 (en) * | 2020-02-10 | 2022-12-21 | SomaLogic Operating Co., Inc. | Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof |
| US20230313299A1 (en) * | 2020-03-02 | 2023-10-05 | Université De Strasbourg | Method for diagnosis and/or prognosis of liver disease progression and risk of hepatocellular carcinoma and discovery of therapeutic compounds and targets to treat liver disease and cancer |
| JP7471898B2 (ja) * | 2020-04-17 | 2024-04-22 | 合同会社Ｈ．Ｕ．グループ中央研究所 | 胆管がんのバイオマーカー |
| CN111748624B (zh) * | 2020-06-08 | 2022-11-04 | 郑州大学第一附属医院 | 用于预测肝癌是否复发的生物标志物 |
| CN111748623B (zh) * | 2020-06-08 | 2022-11-04 | 郑州大学第一附属医院 | 肝癌患者是否复发的预测标志物及试剂盒 |
| CN112961916B (zh) * | 2020-11-10 | 2024-03-12 | 上海市肿瘤研究所 | Akr1c3作为肝癌预后的生物学标志物及其应用 |
| CN112908470B (zh) * | 2021-02-08 | 2023-10-03 | 深圳市人民医院 | 一种基于rna结合蛋白基因的肝细胞癌预后评分系统及其应用 |
| CN113462777A (zh) * | 2021-06-28 | 2021-10-01 | 武汉大学 | P4hb在制备肝细胞癌早期诊断试剂盒及制备或筛选抗肝癌药物中的应用 |
| CN114814001B (zh) * | 2022-03-31 | 2023-02-21 | 武汉大学 | 用于制备肝癌检测试剂的新型代谢标志物及其应用 |
| CN115754290A (zh) * | 2022-09-26 | 2023-03-07 | 浙江大学 | 一种用于检测早期肝癌的试剂盒 |
| CN115807089B (zh) * | 2022-11-14 | 2024-09-13 | 石河子大学 | 肝细胞肝癌预后生物标志物及应用 |
| CN116338189B (zh) * | 2023-01-16 | 2025-08-22 | 浙江大学医学院附属第一医院 | 具有蛋白激酶功能的肿瘤标志物ckb在制备肿瘤诊断产品中的应用 |
| CN116386715A (zh) * | 2023-03-09 | 2023-07-04 | 福建医科大学孟超肝胆医院 | 用于原发性肝细胞癌蛋白质组分子分型诊断的特征蛋白及其应用 |
| CN117607438A (zh) * | 2023-11-23 | 2024-02-27 | 浙江大学 | 一种肝细胞癌鉴别诊断和分化程度检测方法 |
| CN119314683B (zh) * | 2024-12-17 | 2025-02-25 | 吉林大学第一医院 | 一种用于肝移植术后预测系统 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| KR970002255B1 (ko) | 1990-06-11 | 1997-02-26 | 넥스스타 파아마슈티컬드, 인크. | 핵산 리간드 |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE508361T1 (de) | 2001-08-14 | 2011-05-15 | Harvard College | Absolute quantifizierung von proteinen und modifizierten formen davon mittels mehrstufiger massenspektrometrie |
| EP1831697A4 (en) * | 2004-12-09 | 2011-01-26 | Eisai R&D Man Co Ltd | SEARCH FOR TUBULINISOTYPES IN CANCER THERAPY USING HALICHONDRIN B ANALOG |
| EP1828776A4 (en) * | 2004-12-09 | 2010-03-17 | Eisai R&D Man Co Ltd | TUBULINISOTYPE SEARCH IN CANCER THERAPY WITH HEMIASTERLINANALOGES |
| US20080161203A1 (en) * | 2006-12-27 | 2008-07-03 | Su Chun-Lin | Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof |
| GB0704764D0 (en) | 2007-03-12 | 2007-04-18 | Electrophoretics Ltd | Isobarically labelled reagents and methods of their use |
| JPWO2009113495A1 (ja) * | 2008-03-12 | 2011-07-21 | 財団法人ヒューマンサイエンス振興財団 | 肝癌特異的発現遺伝子による肝癌の検査方法並びに肝癌の治療及び予防剤 |
| CA2785389A1 (en) * | 2009-12-25 | 2011-06-30 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent or postoperative adjuvant chemotherapeutic agent for hepatocellular carcinoma treatment |
| HK1199099A1 (en) * | 2011-08-31 | 2015-06-19 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of cancer |
-
2013
- 2013-11-13 GB GBGB1320061.3A patent/GB201320061D0/en not_active Ceased
-
2014
- 2014-11-13 WO PCT/GB2014/053368 patent/WO2015071669A2/en not_active Ceased
- 2014-11-13 CA CA2928510A patent/CA2928510A1/en not_active Abandoned
- 2014-11-13 JP JP2016530873A patent/JP2016538545A/ja active Pending
- 2014-11-13 EP EP14814986.7A patent/EP3069142A2/en not_active Withdrawn
- 2014-11-13 US US15/036,773 patent/US20160320395A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pillet et al. | Comparative evaluation of six commercialized multiplex PCR kits for the diagnosis of respiratory infections | |
| Addanki et al. | Applications of circulating tumor cells and circulating tumor DNA in precision oncology for breast cancers | |
| Mok et al. | Association of kidney disease measures with cause-specific mortality: the Korean Heart Study | |
| Du Preez et al. | The application of metabolomics toward pulmonary tuberculosis research | |
| JP2012508865A5 (enExample) | ||
| GB2478441A (en) | Lung cancer biomarkers and uses thereof | |
| BR112012032537A2 (pt) | biomarcadores de câncer de pulmão e suas utilizações | |
| JP2016507723A5 (enExample) | ||
| CN106885908A (zh) | 血清psmd4蛋白的检测试剂盒及其检测方法与应用 | |
| Liu et al. | The diagnostic role of miR-122 in drug-induced liver injury: a systematic review and meta-analysis | |
| JP2014523521A5 (enExample) | ||
| Guo et al. | Real-time quantitative RT-PCR detection of circulating tumor cells from breast cancer patients | |
| Mansilla et al. | The identification and isolation of CTCs: a biological Rubik’s cube | |
| CN105316404B (zh) | 系统性红斑狼疮生物标志物及其诊断试剂盒 | |
| Torres et al. | Comprehensive determination of prostate tumor ETS gene status in clinical samples using the CLIA decipher assay | |
| McMahon et al. | The role of fecal calprotectin in investigating digestive disorders | |
| JP2016519767A5 (enExample) | ||
| Kosa et al. | Comparison of dual-color dual-hapten brightfield in situ hybridization (DDISH) and fluorescence in situ hybridization in breast cancer HER2 assessment | |
| Andrews et al. | Single cell, single nucleus and spatial RNA sequencing of the human liver identifies hepatic stellate cell and cholangiocyte heterogeneity | |
| Yoon | Recent advances in tumor markers of human hepatocellular carcinoma. | |
| Koga et al. | New molecular diagnosis and screening methods for colorectal cancer using fecal protein, DNA and RNA | |
| Benhammou et al. | DETECT: development of technologies for early HCC detection | |
| JP2018534910A5 (enExample) | ||
| JP2021019612A (ja) | 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 | |
| Miguel et al. | Biological variation and prognosis usefulness of new biomarkers in liver transplantation |